Analysis of multiple endpoints in clinical trials: it's time for the designations of primary, secondary and tertiary to go.
Snapinn
Steven
S
Amgen, Department of Global Biostatistics and Epidemiology, Thousand Oaks, CA 91320, USA. ssnapinn@amgen.com
Jiang
Qi
Q
D002986:Clinical Trials as Topic / Q000706:statistics & numerical data*; D006801:Humans; D012107:Research Design; D013223:Statistics as Topic / Q000379:methods*